NeoGenomics (NEO) has been on a downward spiral lately with significant selling pressure. After declining 29.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

NeoGenomics (NEO) Q2 2025 Earnings Call July 29, 2025 08:30 AM ET Speaker0Good morning, and welcome to the NeoGenomics second quarter two thousand twenty five financial results call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I will now turn the call over to Kendra Webster, vice president of investor relations.Speaker1Thank you, Tom, and good morning, every ...

NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.02 per share when it actually produced break-even earnings, delivering a surprise of +100%.Over the last four quarters, the company has surpassed consensus EPS estimates three ...

2Q 2025 Financial Results Nasdaq: NEO 1 July 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securiti ...

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-35756 Washington, D.C. 20549 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 Florida 33912 Nevada 74-2897368 (Address of principal executive ...

Exhibit 99.1 NeoGenomics Reports Second Quarter 2025 Results Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance Fort Myers, Florida (July 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 202 ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Zeo Energy Corp and its officers or directors [1] Group 1: Company Compliance Issues - On May 29, 2025, Zeo announced it received a notice from Nasdaq regarding non-compliance with periodic filing requirements due to the failure to file its Quarterly Report on Form 10-Q by the due date of May 15, 2025 [2] - Following this announcement, Zeo's stock price decreased by $0.34 per share, representing a decline of 9.91%, closing at $3.09 per share on May 30, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Insights - NEO Battery Materials Ltd. has achieved significant advancements with its P-300N silicon battery, surpassing long-term capacity testing metrics with over 90% capacity retention for 300 cycles, exceeding the target of 80% [2][10] - The company has appointed Dr. Jun Sik Jeoung as Senior Vice President to lead large-scale battery testing and production expansion, leveraging his extensive experience in the battery industry [3][10] - The results from the P-300N testing enable NEO to move forward with large-cell format testing and the design of single-layer pouch cells, which will undergo long-term performance tests [4][10] Company Developments - NEO is actively preparing for multi-layer cell testing and is in discussions with battery prototypers and manufacturers in South Korea, the U.S., and Germany for outsourcing manufacturing [5][10] - The company has secured post-treatment equipment and is nearing completion of installation at its R&D Scale-Up Centre, which will enhance production capacity and quality [6][10] - The 2025 Annual General and Special Meeting resulted in all resolutions being approved by shareholders, including the appointment of MNP LLP as auditor and setting the number of directors at five [7][9][11] Technical Achievements - The P-300N battery prototype is recognized as one of the most stable silicon battery materials in the global supply chain, utilizing metallurgical silicon (MG-Si), which is the lowest-cost silicon input for battery-grade applications [2][14][10] - The engineering team has initiated the design and architecture of single-layer pouch cells, which will optimize interactions between P-300N, graphite anodes, and various cathode materials [4][10] - The company aims to fulfill elevated requests from global downstream partners by adding a key manufacturing unit to expand overall capacity [6][10]

Summary of NeoGenomics Conference Call Company Overview - **Company**: NeoGenomics (NEO) - **Industry**: Life Sciences and Oncology Diagnostics Key Points and Arguments Leadership Insights - The new CEO, Tony, has observed strengths in NeoGenomics that were previously underestimated, particularly in the hospital community and hematology [1][2] - The company has a strong focus on therapy selection, with 22% of revenue driven by recent product launches [2] Financial Guidance - NeoGenomics initially guided for 11% to 13% revenue growth for 2025, which includes contributions from the Pathline acquisition [7][8] - The Pathline acquisition is expected to contribute $12 million to $14 million in revenue for the year [27] - Revenue growth in 2024 was 12%, with 16% growth in 2023, and clinical business grew by 15% in 2024 [9] Sales Force Expansion - The company added 30 sales representatives, a 25% increase, focusing on community oncology [10] - It typically takes 6 to 9 months for new sales reps to reach full productivity [14] - The sales strategy includes targeting high-potential physicians based on their prescription writing [17] Product Launches and Pricing - New product launches, including PANTRACER liquid, are expected to drive growth in the second half of the year [11][22] - A direct client bill price increase was implemented in Q1, expected to benefit margins throughout the year [25] Operational Efficiency - NeoGenomics is focused on improving turnaround times and operational execution to enhance customer retention and acquisition [19] - The company is investing in automation and has a project underway to consolidate multiple lab information systems into one [58][62] Partnerships and Market Positioning - The partnership with Adaptive Biotechnologies aims to enhance the workflow for physicians by allowing combined requisitioning of tests [35][38] - The company is also exploring opportunities in the MRD (Minimal Residual Disease) market, focusing on sensitivity and tissue-informed testing [41][46] Market Dynamics - The MRD market is currently under-penetrated, with significant opportunities in community settings [46] - Guidelines for circulating tumor DNA testing are anticipated, which could drive broader adoption [51][52] Capital Deployment Strategy - NeoGenomics plans to balance investments in growth with potential stock buybacks and debt repayment, aiming for positive free cash flow by 2026 [64][65] Additional Important Insights - The company is leveraging its strengths in community oncology and is optimistic about future partnerships and licensing opportunities [34] - The integration of Pathline is ongoing, with expectations for economies of scale in NGS (Next Generation Sequencing) testing [28] - The focus on operational efficiencies through robotics and AI in lab processes is seen as a key growth driver over the next few years [62][63]

Summary of NeoGenomics (NEO) FY Conference Call - June 03, 2025 Company Overview - **Company**: NeoGenomics - **CEO**: Tony Zuck, who joined a few months prior to the conference but has been associated with the company for two years as a board member [4][3] Industry Insights - **Cancer Statistics**: One in two men and one in three women will face cancer in their lifetime, highlighting the significant market for cancer diagnostics [7] - **Patient Treatment Preferences**: 80% of cancer patients prefer to be treated in their local community, which informs NeoGenomics' strategy to focus on community hospitals [9] Strategic Positioning - **Market Position**: NeoGenomics operates between large clinical reference labs and Oncotechs, with over 500 test offerings, focusing on oncology [10][12] - **Market Size**: The cancer diagnostic testing market is approximately $12 billion, with a penetration rate of 70%. The therapy selection market is about $13 billion with a 35% penetration rate, and the MRD market is estimated at $30 billion with only 5-8% penetration [13][15] Growth Strategy - **Community Focus**: The company aims to provide the same level of cancer care in community settings as found in top hospitals [10] - **Revenue Growth**: NeoGenomics has achieved 8% year-on-year growth in volume and anticipates continued growth driven by new product offerings and market expansion [34][44] - **Sales Force Expansion**: The sales force has been expanded to 140 representatives, focusing on oncology practices [35] Product Development - **New Product Launches**: The PANTRACER product suite, including liquid biopsy and tissue tests, is set to launch, enhancing the company's oncology portfolio [39][40] - **Research and Development**: Emphasis on next-generation precision diagnostic solutions, particularly in MRD and therapy selection [27][28] Financial Performance - **Revenue Growth**: Revenue increased from approximately $484 million in 2021 to over $660 million in 2024, with a positive EBITDA of $40 million [42][43] - **Future Projections**: Expected revenue growth of 13% to 15% for the current year, with adjusted EBITDA growth of 38% to 45% [44] Strategic Acquisitions - **Pathline Acquisition**: Acquired Pathline to strengthen the company's presence in the Northeast, enhancing service capabilities and turnaround times [37][46] Conclusion - **Optimistic Outlook**: The company is positioned for sustainable growth through its community-focused strategy, innovative product offerings, and operational efficiencies [48][49]